Investor Relations

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).

NASDAQ | AVEO (Common Stock)
$0.94 + 0.02
Stock chart for: AVEO.O.  Currently trading at $0.94 with a 52 week high of $2.90 and a 52 week low of $0.82.
05/27/16 4:00 p.m. ET
Data Provided by Thomson Reuters

Press Releases

AVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell CarcinomaRead More
AVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell CancerRead More
AVEO Announces $17 Million Private PlacementRead More

Latest Event